Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

Kobe Biomedical Innovation Cluster, Title Sponsor of RESI San Diego 2026, to Host Japan Life Science Showcase

14 Apr

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is pleased to announce Kobe Biomedical Innovation Cluster (KBIC) as a Title Sponsor of RESI San Diego 2026.

Earlier this year at RESI JPM 2026, LSN and KBIC successfully co-organized the Kansai Life Science Accelerator Program (KLSAP) Demo Day, a 2-hour session highlighting innovative companies from Japan and South Korea. Building on this successful collaboration, KBIC will host the Japan Life Science Showcase at RESI San Diego, featuring 8 emerging life sciences companies from Japan. This dedicated showcase aims to highlight cutting-edge technologies and connect Japanese innovators with global investors and strategic partners.

The impact of the KLSAP Demo Day and RESI was reflected in strong feedback from participating companies:

“Celaid Therapeutics Inc. participated in JPM RESI 2026 through the full RESI package, which included a RESI-organized pitch to U.S.-based investors, an exhibition booth, and one-on-one partnering meetings. The IPC investor pitch was particularly valuable. Following the presentation, we were contacted by one of the investor judges, which subsequently led to further meetings regarding a potential investment. For early-stage companies seeking investment from U.S. investors, this program is well worth considering.”

— Yusuke Inoue, Board Director, COO & CFO, Celaid Therapeutics Inc.

Japan is home to one of the world’s most advanced life sciences ecosystems, supported by strong academic research, a highly skilled talent base, and increasing government and institutional support for innovation. Within this landscape, Kobe has established itself as a leading hub for biomedical innovation, fostering collaboration across academia, industry, and clinical institutions. Through the Japan Life Science Showcase at RESI San Diego, KBIC seeks to further elevate Japan’s presence on the global stage and accelerate cross-border partnerships.

More information about the presenting companies will be announced shortly. Please feel free to contact us at c.jeong@lifesciencenation.com if you would like to stay updated on related developments.

RESI San Diego will take place on Monday, June 22, at the JULEP Venue in San Diego. Join us for a full day of one-on-one partnering meetings, engaging programming, and the opportunity to build meaningful connections within the global life sciences ecosystem.

About Kobe Biomedical Innovation Cluster (KBIC)

Located in the heart of Kobe, Japan, the Kobe Biomedical Innovation Cluster is one of the nation’s leading ecosystems dedicated to advancing biomedical research and commercialization. With more than 340 member organizations, including research institutes, hospitals, and life science companies, KBIC plays a central role in bridging academia, government, and industry to accelerate innovation and improve global health outcomes.

As a Title Sponsor of RESI San Diego 2026, KBIC aims to strengthen international collaboration and support Japanese startups in expanding their global networks and visibility. Through its continued partnership with LSN, KBIC is committed to helping founders access global capital and strategic resources to advance their technologies from concept to commercialization.

Register for RESI San Diego

Tags: , , , , , , , , , , , , ,

From Proof to Approval: Regulatory Risk 

14 Apr

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

As part of Life Science Nation’s series on converting scientific innovation into investable signal, the focus now moves to the next layer of the De-Risk Stack. In the previous article, technical risk addressed whether a product works and can be trusted. The next question is whether it can realistically be approved.

This article examines regulatory risk, where feasibility must become predictability. It outlines how companies define a clear path to approval—covering regulatory pathways, precedent, endpoint selection, trial design, and engagement with regulators.

From aligning with evidence requirements to understanding timelines and cost, this piece breaks down what it takes to move from promising data to an executable plan that investors can underwrite.

Regulatory Risk 

From Feasibility to Predictability

Once the product works, the next question is whether it can be approved.

Regulatory risk is often underestimated because it is treated as an after-the-fact compliance requirement instead of a primary design constraint. In reality, it defines timelines, capital requirements, and feasibility. Without a credible path, investment becomes difficult regardless of how strong the data may be.

The core issue is predictability. Investors need to understand not just that approval is possible, but how it will be achieved, how long it will take, and what it will cost.

This begins with pathway clarity. The regulatory route must be defined early—whether the asset is headed toward an IND and NDA/BLA, a 510(k), a PMA, or another pathway. Precedent provides context by showing how similar products, mechanisms, or indications have been evaluated. Without precedent, uncertainty and perceived risk rise sharply.

Endpoints and trial design then determine whether the plan is executable. Success must be measurable in a way regulators accept, and the required studies must be feasible in terms of recruitment, duration, complexity, and cost. A theoretically elegant trial that cannot be run in the real world is equivalent to having no trial plan at all.

Regulatory interaction further refines the path. Pre-IND or pre-submission meetings align expectations, clarify requirements, and reduce unnecessary iteration. Proceeding without this engagement increases risk and can lead to expensive rework.

Safety requirements, timeline expectations, and the cost of approval define the remaining boundaries. Each indication and modality carries a different tolerance for risk and a different evidence bar, and each pathway implies a specific capital profile.

Regulatory risk is resolved when the path to approval is defined, evidence requirements are understood, and the plan is both credible and executable within known time and capital constraints.

Core Elements of Regulatory Risk 

  • Pathway clarity
  • Precedent
  • Endpoint definition
  • Trial design feasibility
  • Regulatory interaction
  • Safety requirements
  • Timeline predictability
  • Cost of approval

Next in the series: Execution Risk — Turning Plan into Progress 

Previous Articles：

Technical Risk – From Belief to Evidence

The Problem Is Not the Science: A Seven-Part Series on De-Risking, Signal, and Investability

Tags: , , , , , , , , , , , , , , ,

Innovator’s Pitch Challenge Winner Spotlight: Bram De Moor of You2Yourself 

14 Apr

Following its recognition as a winner of the Innovator’s Pitch Challenge at RESI Europe, You2Yourself is advancing a new approach to early disease detection through longitudinal biomarker monitoring. In this interview, Bram De Moor discusses the science behind URIMON, the company’s commercialization strategy, and how RESI has supported its investor engagement. 

Bram De Moor
Founder & General Manager, You2Yourself
 CaitiCaitlin Dolegowski
Program Director, LSN

Caitlin Dolegowski (CD): For those new to You2Yourself, how would you describe URIMON and the value of longitudinal biomarker monitoring in a way that resonates with investors?

Bram De Moor (BD): URIMON is a personalized, non-invasive, urine-based liquid biopsy platform that uses urinary miRNA profiling to detect multiple serious diseases — including prostate cancer, lung cancer, and cardiovascular disease — before symptoms appear. One urine sample generates simultaneous risk scores across multiple conditions.

The longitudinal dimension is key: repeated monitoring detects biological drift months to years before clinical symptoms — the difference between catching cancer at stage I versus stage III. With no needles, no clinic visit, and at-home collection with mail-in capability, URIMON is designed for scalable, population-level adoption.

CD: What makes your approach to early disease detection fundamentally different from traditional diagnostic models?

BD: Traditional diagnostics are reactive and often focus on a single biomarker. URIMON differs in three key ways:

  • Multi-disease detection from a single sample, analyzing hundreds of miRNA species simultaneously
  • Focus on molecular signals rather than anatomical changes, enabling earlier detection
  • Use of urine as a scalable, patient-friendly biofluid that captures signals from across the body

This approach provides a unified molecular health view, reducing fragmentation across specialties.

CD: You have built a unique biobank of longitudinal samples — how does this dataset strengthen your technology and create a competitive advantage?

BD: The URIMON Biobank, developed since 2019 with over 6,500 participants under IRB-approved and GDPR-compliant protocols, is a significant strategic moat.

It enables algorithm training on longitudinal patient data, including individuals who later develop disease, supporting prospective validation. It also ensures robustness across cohorts, allowing classifiers to generalize beyond a single institution.

Replicating this dataset would require years and substantial capital, making it a durable barrier to entry.

CD: How do you think about commercialization, particularly your subscription-based model and the path toward broader reimbursement and population-level adoption?

BD: Our strategy is staged to de-risk scaling. We are entering the market under the EU IVDR Article 5(5) in-house LDT framework to accelerate time to revenue.

Our subscription model (€299–499/year) targets individuals, employer groups, and occupational health programs, aligning recurring revenue with longitudinal monitoring.

Reimbursement will follow through HTA submissions in Europe, with FDA De Novo clearance as a parallel pathway in the U.S.

CD: What key milestones or inflection points should investors be watching as you move toward your planned 2027 market entry?

BD: Key milestones include:

  • Clinical validation and publication of performance data
  • Regulatory progress under IVDR and FDA pathways
  • Launch of commercial infrastructure and first paying customers
  • Strategic partnerships and completion of financing rounds
  • These milestones will demonstrate both technical validation and commercial traction.

CD: How did participating in RESI Europe and the Innovator’s Pitch Challenge impact your investor visibility and strategic conversations?

BD: RESI provided direct access to European and transatlantic investors actively seeking early-stage diagnostic companies — a highly targeted audience that is difficult to reach through traditional outreach.

The Innovator’s Pitch Challenge offered structured validation in a competitive setting, signaling credibility to institutional investors. It also led to new investor conversations and follow-up meetings now underway.

CD: Following your recognition at RESI Europe, what are the next key priorities for You2Yourself as you move into your next phase of growth?

BD: Our focus over the next 12–18 months includes:

  • Expanding clinical evidence through continued biobank growth and prospective studies
  • Securing financing through grants and a seed-to-Series A bridge round
  • Scaling team and infrastructure across lab, regulatory, and business development functions

With favorable market conditions — including advances in NGS, growing demand for preventive health, and regulatory clarity — You2Yourself is well positioned to lead in this space.

Applications are now open for upcoming Innovator’s Pitch Challenges. Companies can apply to pitch at RESI San Diego 2026 and take the stage in front of a global network of investors and partners.

Apply to Pitch at RESI San Diego

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Technical Risk – From Belief to Evidence 

7 Apr

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

In the first article, The Problem Is Not the Science, Life Science Nation established that investability begins with defining a real, urgent market need. But once that foundation is clear, the next question becomes unavoidable: does the product actually work, and can that be demonstrated in a way others trust?

The next focus is technical risk, where belief must become evidence. It outlines how companies move from early signals to reproducible, credible, and translatable results—covering mechanism of action, proof of concept, reproducibility, safety, and scalability.

Once market risk is clear, the next question becomes unavoidable: does the product work, and can that be demonstrated in a way that others trust?

This is where many companies overestimate their position. Early data, promising signals, or strong academic foundations often create internal confidence. But investors are not evaluating belief; they are evaluating evidence. The distance between those two states defines technical risk.

Technical risk is not simply about whether something works once. It is about whether it works consistently, whether the mechanism is credible, and whether the results can survive the transition from controlled environments into real-world use.

The first layer of clarity comes from the mechanism of action. There must be a coherent explanation of how the biology or technology produces the intended effect. This is not a description of experimental outcomes; it is a causal story. Without it, data is difficult to interpret and harder to trust.

Proof of concept establishes that the signal exists. This can take the form of in vitro data, animal models, early human data, or a working prototype, but it must be observable and measurable. Reproducibility then determines whether that signal can be relied upon. A single experiment is not enough. Results must hold across time, cohorts, and independent attempts.

Translatability introduces another layer of complexity. What works under ideal conditions does not always work in patients, clinics, or real-world settings. Understanding how findings extend beyond the initial model is critical, particularly in biologically complex indications.

Safety, performance, and durability define the product profile. Even if effective, a product must be safe enough for its intended use, deliver a meaningful effect, and sustain that effect over time. A transient or marginal benefit rarely justifies the cost and risk of development.

Finally, manufacturability, scalability, and data integrity complete the picture. A product that cannot be produced consistently and at scale cannot become a company. Data that is poorly designed, uncontrolled, or selectively presented undermines confidence, even when the underlying science is strong.

Technical risk is resolved when the product moves from an interesting idea to something that consistently works, can be trusted, and can be translated into real-world use.

Core Elements of Technical Risk

  • Mechanism of action
  • Proof of concept
  • Reproducibility
  • Translatability
  • Safety
  • Performance and durability
  • Manufacturability and scalability
  • Data quality and integrity

Next in the series: Regulatory Risk — Navigating the Path to Approval

Tags: , , , , , , , , , , , , , , ,

How Early-Stage Companies Should Think About June in San Diego 

7 Apr

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

Whether in San Diego, Philadelphia, or Boston, there are a handful of weeks each year when the life science industry gathers in force. Founders, investors, pharma, and advisors all show up at once. Multiple events run in parallel, each with its own programming, audience, and purpose. From the outside, it looks like one opportunity.

It is not.

Each event is designed to serve a specific audience. Some programs are intentionally broad and inclusive. They bring together large numbers of participants across the ecosystem and create a wide surface for interaction. Others are more focused. They are designed to reach a narrower audience with a specific objective.

The challenge for early-stage companies is that it is not always obvious which environment they are actually entering.

Most of the broader convention programming is built around partnering between established biotech companies and large pharma. These conversations assume a certain level of maturity. The data has been prepared for external review. Development paths are clearer. The work is far enough along for a downstream buyer to evaluate.

For companies at that stage, the environment works. For earlier-stage companies, the situation is different.

They enter the same system, but the conversations are not always aligned with what they need. Licensing discussions can be premature. Data packages are still forming. Investor meetings are possible, but they are not the primary function of the week. Competition for attention is high, and much of that attention is directed toward later-stage opportunities.

Nothing is wrong with the environment. It is doing exactly what it is designed to do.

The issue is alignment.

Early-stage companies are not primarily seeking licensing outcomes. They are seeking capital. Capital behaves differently. It requires a higher concentration of relevant investors, a structure built around evaluation, and conversations that lead to funding decisions. Seed rounds up to two million, Series A up to ten million, and Series B up to fifty million are fundamentally different conversations than late-stage programs discussing Phase III data, scaling, and commercial expansion with pharma. They are different buyers, different expectations, and different decision processes.

During that same week, RESI operates as a separate market focused on early-stage capital formation. The investor base is concentrated around seed through Series A and early Series B. The conversations are centered on investment. The environment is designed to match companies with investors who are actively deploying capital into emerging opportunities.

This creates a different dynamic.

Instead of competing for limited attention in a broad, later-stage environment, companies operate in a setting where the density of relevant investors is higher, and conversations are aligned with their stage. This is not a question of which event is better.

The question is whether you are in the right room.

If your objective is licensing or a strategic partnership with large pharma, the broader convention environment is the right place to spend your time. If your objective is to raise capital at the early stage, the question becomes more direct. Where are the investors actively deploying to companies like yours, and how concentrated are they? Many companies try to do both. Some can. Most dilute their effort. The cost is not just the registration fee. It is time, focus, and missed opportunity. In weeks like this, the difference between being in the right room and the wrong one is not subtle. Please choose a room that fits your stage.

Register for RESI San Diego

Tags: , , , , ,

Extend Your Reach Across Two Key Life Science Markets 

7 Apr

By Matt Stanton, VP Sales US West, Central and South America, LSN

For companies navigating fundraising or business development, timing and consistency matter as much as the initial introduction. The RESI San Diego 2026 and RESI Boston 2026 bundle is structured to support both, offering a coordinated approach to investor and partner engagement across two high-activity windows. 

By combining these events, organizations can move beyond one-off meetings and build sustained momentum with the same network of investors and strategic partners over time. 

Two Events. One Continuous Engagement Strategy 

The bundle includes full 5-day access to both conferences: 

RESI San Diego 2026
June 22 (in-person during Convention Week) followed by four days of virtual partnering 

RESI Boston 2026
September 22–23 (in-person during Biotech Week Boston) followed by three days of virtual partnering 

Positioned three months apart, these events create a natural progression—from initial outreach and early conversations in San Diego to deeper follow-up and potential deal advancement in Boston. 

Built for How Deals Actually Happen 

Fundraising and BD are iterative processes. Initial meetings rarely lead directly to outcomes; they require follow-up, validation, and continued visibility. This bundle is designed with that reality in mind. 

Participating in both RESI events allows organizations to maintain continuity by: 

  • Re-engaging investors and partners across multiple touchpoints  
  • Strengthening credibility through consistent presence  
  • Advancing discussions with greater context and traction  

Rather than restarting conversations, companies return to Boston with warmer leads and clearer positioning. 

Limited-Time Bundle Pricing 

Discount rates are available for a limited time: 

  • Startups: From $3,490 (regularly $4,490)  
  • Service Providers: From $4,490 (regularly $5,490)  

Savings of up to $1,000 are available through April 17. 

A More Effective Way to Build Pipeline 

The RESI ecosystem is built on repeated, data-driven engagement across a global network of investors, innovators, and partners. The San Diego & Boston bundle aligns with this model—providing a structured way to build pipeline, maintain visibility, and convert conversations into outcomes. 

To register, select the bundle ticket option within the RESI San Diego registration portal.

Register for RESI San Diego and Boston Bundle

Tags: , , , , , ,

The Problem Is Not the Science: A Seven-Part Series on De-Risking, Signal, and Investability 

31 Mar

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

Early-stage life science companies do not fail because the science is weak. They fail because the science never becomes investable. Across therapeutics, devices, diagnostics, and digital health, failure rates approach ninety percent. The default explanation is technical risk. The data did not hold. The biology did not translate. The product did not perform. That is not what usually happens. What happens is structural. Companies are built without a system for converting discovery into something capital can evaluate, compare, and act on. They generate data before defining the problem. They raise capital before removing uncertainty. They move forward without knowing what the next decision-maker needs to see. Capital does not fund ideas. It funds signal.

Signal is what allows an investor or partner to act with confidence. It is produced when specific forms of uncertainty are systematically removed. Without signal, even strong science remains interesting but unfundable. With it, capital moves. Over the next six articles, we will break down how that signal is created. Not through storytelling, but through the systematic reduction of risk across a defined stack. Each layer represents a different barrier to action. Each must be addressed in sequence. Investability emerges when enough of this stack has been reduced to a level that supports a decision.

  • Market
  • Technical
  • Regulatory
  • Execution
  • Economic
  • Financing
  • Exit

The series begins where it should: with market risk. Market risk sits at the foundation. Before anything else, a real and meaningful problem must be established. It is not enough to have a promising technology. The problem must be precise, urgent, and actionable within a real system.

The clarity of the unmet need defines the problem. Urgency determines whether action is required. Identification of the buyer clarifies who decides and who pays. The current standard of care provides context for change. Differentiation defines why the product matters. Adoption friction determines how difficult implementation is. Path to payment ensures the product can be funded. If these elements are not clear, the company is not ready. It is undefined. Most companies move past this step too quickly. They begin with the science and assume the market will follow. By the time they realize it has not, they have already consumed time, capital, and credibility. When market risk is resolved, everything else begins to align. Technical work becomes purposeful. Regulatory paths become clearer. Economic value can be measured. Capital has something to anchor to. Signal begins to form.

This is where the series starts. In the articles that follow, we will move layer by layer through the stack, showing how each dimension of risk is defined, reduced, and translated into investable signal. The objective is not to simplify science. It is to make the path from discovery to capital legible and executable. The challenge in life science is not discovery.

It is the disciplined conversion of discovery into investable signal.

Market Risk

Defining Whether a Real Problem Exists

At the foundation of the De-Risk Stack is market risk. Before a founder thinks about technical validation, regulatory pathway, or fundraising strategy, there is a more basic question: does this company solve a real problem in a form the market will recognize and respond to?

This is where many early-stage life science ventures begin to drift. A founder may have compelling science, a large disease category, and years of academic work behind the technology, yet still fail to define the problem in commercial terms. Capital does not fund scientific possibilities in the abstract; it funds opportunities where a specific problem is understood, urgent, and attached to a buyer who has a reason to act.

Market risk is therefore not a question of size alone. A very large indication can still represent a weak opportunity if the unmet need is vague, the current standard of care is acceptable, or the path to payment is unclear. By contrast, a narrowly defined indication with a highly specific unmet need can be highly investable when urgency is high, the buyer is identifiable, and the product’s advantage is obvious. What matters is not breadth, but clarity.

In practice, market risk begins with the definition of unmet need. The problem must be described precisely enough that an investor, clinician, or partner can understand exactly what is broken and for whom. Urgency follows. Some conditions create pressure for action because they are life-threatening, progressive, poorly managed, or economically burdensome. Others do not. That distinction shapes adoption, tolerance for risk, and willingness to pay.

Once need and urgency are clear, attention shifts to the buyer and the system. In life science, the user, decision maker, and payer are often different actors. If you cannot identify who decides and who pays, you do not yet have a real market thesis. At the same time, every product enters an existing standard of care. You must understand how patients are currently treated, where those approaches fail, and why change is justified.

Differentiation, adoption friction, and path to payment complete the picture. A product must be better in a way that matters—not just marginally improved in a way that is difficult to notice. It must fit into real workflows, incentives, reimbursement structures, and budget constraints. If the system cannot absorb the product, market risk remains unresolved, no matter how attractive the science appears.

Market risk is resolved when a clearly defined and urgent problem exists, a real buyer is identified, the current approach is inadequate, and the product has a credible path to adoption and payment.

Core Elements of Market Risk

  • Clarity of unmet need
  • Urgency
  • Identification of the buyer
  • Current standard of care
  • Differentiation
  • Adoption friction
  • Path to payment

Market risk is the first layer of the De-Risk Stack, but it is only the beginning. Resolving whether a real, urgent problem exists establishes the foundation for everything that follows. Without it, progress elsewhere does not translate into investability.

This series examines each layer of the stack in sequence, outlining how risk is systematically reduced to convert scientific innovation into something capital can evaluate and fund.

In the next installment, the focus shifts to technical risk: how companies demonstrate that their product works, and how to de-risk the underlying technology in a way that builds investor confidence.

Check back next week for Technical Risk: De-Risking the Stack.

Tags: , , , , , , , , , , , , ,

← Older Entries
Newer Entries →